Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

V Lorenzi

Showing results (61-70 of 67) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 67 results.
Leukemia|October 22, 2011
Characterization of BMS-911543, a functionally selective small-molecule inhibitor of JAK2A V Purandare, T M McDevitt, H Wan, et al.
Cell|January 27, 2018
Targeting KRAS Mutant Cancers with a Covalent G12C-Specific InhibitorMatthew R Janes, Jingchuan Zhang, Lian-Sheng Li, et al.
Nature|June 15, 2007
A giant outburst two years before the core-collapse of a massive starA Pastorello, S J Smartt, S Mattila, et al.
ACS Medicinal Chemistry Letters|August 20, 2015
Discovery of a Highly Selective JAK2 Inhibitor, BMS-911543, for the Treatment of Myeloproliferative NeoplasmsHonghe Wan, Gretchen M Schroeder, Amy C Hart, et al.
Molecular Cancer Therapeutics|September 29, 2021
Discovery and Pharmacological Characterization of JNJ-64619178, a Novel Small-Molecule Inhibitor of PRMT5 with Potent Antitumor ActivityDirk Brehmer, Lijs Beke, Tongfei Wu, et al.
Iscience|March 10, 2025
JNJ-78306358, a first-in-class bispecific T cell engaging antibody targeting CD3 and HLA-GNataša Obermajer, Adam Zwolak, Kelly van de Ven, et al.
Journal of Medicinal Chemistry|April 1, 2026
Optimization of Covalent 6-Cyanoquinazoline KRAS<sup>G12C</sup> Inhibitors for the Treatment of Solid TumorsJesse P Waldo, Paul J Krawczuk, Christopher B Kelly, et al.
Pageof 7

Showing results (61-70 of 67) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 67 results.
Leukemia|October 22, 2011
Characterization of BMS-911543, a functionally selective small-molecule inhibitor of JAK2A V Purandare, T M McDevitt, H Wan, et al.
Cell|January 27, 2018
Targeting KRAS Mutant Cancers with a Covalent G12C-Specific InhibitorMatthew R Janes, Jingchuan Zhang, Lian-Sheng Li, et al.
Nature|June 15, 2007
A giant outburst two years before the core-collapse of a massive starA Pastorello, S J Smartt, S Mattila, et al.
ACS Medicinal Chemistry Letters|August 20, 2015
Discovery of a Highly Selective JAK2 Inhibitor, BMS-911543, for the Treatment of Myeloproliferative NeoplasmsHonghe Wan, Gretchen M Schroeder, Amy C Hart, et al.
Molecular Cancer Therapeutics|September 29, 2021
Discovery and Pharmacological Characterization of JNJ-64619178, a Novel Small-Molecule Inhibitor of PRMT5 with Potent Antitumor ActivityDirk Brehmer, Lijs Beke, Tongfei Wu, et al.
Iscience|March 10, 2025
JNJ-78306358, a first-in-class bispecific T cell engaging antibody targeting CD3 and HLA-GNataša Obermajer, Adam Zwolak, Kelly van de Ven, et al.
Journal of Medicinal Chemistry|April 1, 2026
Optimization of Covalent 6-Cyanoquinazoline KRAS<sup>G12C</sup> Inhibitors for the Treatment of Solid TumorsJesse P Waldo, Paul J Krawczuk, Christopher B Kelly, et al.
Pageof 7